The aim is to investigate the feasibility, safety, and complication rates of patient's self-measurement of CBC and self-administration of blood and platelet transfusions at home and examine the performance of patients conducting at-home monitoring of their blood pressure, pulse rate, saturation, and temperature before and after transfusion. Furthermore, to evaluate the health economic consequences of our innovative approach, specifically, the anticipated reduction in reliance on nurse-driven services. This study is a single-arm feasibility study with patients newly diagnosed with Acute Myeloid Leukemia. The study will be conducted at the Department of Hematology, Rigshospitalet. Patients are included if they are ≥ 18 years old, newly diagnosed with AML within four weeks, and scheduled to receive home-based chemotherapy. Patients are excluded if they do not speak Danish or are not assessed to be capable of performing home-based CBC measurements and administration of transfusions. Patients will be discontinued if they do not achieve remission after the second chemotherapy cycle. Included patients will receive comprehensive training and certification to perform CBC measurements, self-administer transfusions, and monitor selected vital parameters including blood pressure, pulse rate, oxygen saturation, and temperature. It is hypothesized that the study can demonstrate the logistic, technical, and economic feasibility and safety of educating patients with AML undergoing intensive chemotherapy, to independently conduct self-measurement of complete blood count (CBC), self-administration of transfusions at home, and examine the performance of patients conducting at-home monitoring of their blood pressure, pulse rate, saturation, and temperature before and after transfusion.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Technical Performance of the Hemoscreen Instrument
Timeframe: Assessed throughout each participant's enrollment period, up to 12 weeks.
Self-Administered Blood Measurements at Home
Timeframe: Recorded continuously during each participant's enrollment, up to 12 weeks.
Self-Administered Blood and Platelet Transfusions at Home
Timeframe: Recorded continuously during each participant's enrollment, up to 12 weeks.
Replacement of Scheduled Day Hospital Visits by Home Care and Self-Testing
Timeframe: Recorded continuously during each participant's enrollment, up to 12 weeks.
Vital Signs Before and After Home Transfusions
Timeframe: Recorded at each home transfusion event during the participant's 12-week enrollment.
Extra Healthcare Visits and Hospital Admissions
Timeframe: Recorded continuously during each participant's enrollment, up to 12 weeks.
Transfusion Reactions and Adverse Events
Timeframe: Assessed continuously during and for 24 hours post-transfusion within each participant's study period, up to 12 weeks.
Types of Transfusion Reactions
Timeframe: Recorded at each transfusion event during each participant's enrollment up to 12-week study period.